Veracyte, Inc. (VCYT) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $42.52: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 10%; Elevated put/call ratio: 2.33.
Veracyte is a global diagnostics company offering molecular tests for cancer including Decipher Prostate, Afirma (thyroid), Prosigna (breast), and Decipher Bladder, performed in CLIA labs in California and Texas plus IVD distribution internationally. Revenue comes from testing... Read more
Sell if holding. Engine safety override at $42.52: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 10%; Elevated put/call ratio: 2.33. Chart setup: Death cross but MACD improving, RSI 78. Score 5.9/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Veracyte, Inc.
Latest news
- Veracyte (VCYT) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance Singapore — Yahoo Finance Singapore positive
- Earnings Flash (VCYT) Veracyte, Inc. Posts Q1 Adjusted EPS $0.52 per Share - marketscreener.com — marketscreener.com positive
- Wall Street analysts think Veracyte (VCYT) could surge 39.16%: Read this before placing a bet - MSN — MSN positive
- Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.16%: Read This Before Placing a Bet - Zacks Investment Researc — Zacks Investment Research positive
- A Look At Veracyte (VCYT) Valuation As New Decipher Bladder And Prostate Data Heads To AUA 2026 - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDecipher Prostate and Afirma tests10-K Item 1A: 'financial results currently depend mainly on sales of our Decipher Prostate and Afirma laboratory developed tests (LDTs)'
- MEDIUMCustomerMedicare Fee-For-Service34%10-K Item 1: 'Medicare Fee-For-Service accounted for 34%, 33% and 35% of our testing revenue'
- HIGHSuppliersole suppliers for reagents, equipment, and materials10-K Item 1A: 'We rely on sole suppliers for some of the reagents, equipment, and other materials used to perform or develop our tests, as well as certain sole source providers for kit components'
Material Events(8-K, last 90d)
- 2026-03-16Item 5.02LOWVeracyte appointed Dr. Kevin Haas (age 40), former CTO at Myriad Genetics, as Chief Development and Technology Officer effective March 24, 2026. New role; no departure cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Volatile — 5.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $42.52: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10. Specifically: High short interest: 10%; Elevated put/call ratio: 2.33. Chart setup: Death cross but MACD improving, RSI 78. Prior stop was $39.71. Score 5.9/10, moderate confidence.
Take-profit target: $42.14 (-1.3% upside). Prior stop was $39.71. Stop-loss: $39.71.
Concentration risk — Product: Decipher Prostate and Afirma tests; Concentration risk — Supplier: sole suppliers for reagents, equipment, and materials; Target reached (-3.4% upside).
Veracyte, Inc. trades at a P/E of 38.6 (forward 21.9). TrendMatrix value score: 5.2/10. Verdict: Sell.
19 analysts cover VCYT with a consensus score of 4.2/5. Average price target: $47.
What does Veracyte, Inc. do?Veracyte is a global diagnostics company offering molecular tests for cancer including Decipher Prostate, Afirma...
Veracyte is a global diagnostics company offering molecular tests for cancer including Decipher Prostate, Afirma (thyroid), Prosigna (breast), and Decipher Bladder, performed in CLIA labs in California and Texas plus IVD distribution internationally. Revenue comes from testing services billed to Medicare (34%), Medicare Advantage (18%), and commercial payers (47%).